CADLCandel Therapeutics, Inc.Signing up patients
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Prostate Cancer Patients Treated by Radiotherapy · Prostate Cancer (Adenocarcinoma)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 45 (planned)
- Started
- Oct 30, 2025
- Main results expected
- Feb 2027
- Fully finished
- Feb 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Biodistribution of aglatimagene besadenovec
Measured over: Up to 5 months post last injection of aglatimagene besadenovec.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07332000 · record last updated 2026-09-15 · checked 2026-11-09 15:42 UTC